Use access key #2 to skip to page content.
$19.66 -0.32 (-1.60%)
7/18/2008 4:00 PM

Pharmasset, Inc. (VRUS)

CAPS Rating:
*

A clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating VRUS

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

41 Outperforms
32 Underperforms
 

All-Stars

14 Outperforms
20 Underperforms
 

Wall Street

6 Outperforms
0 Underperforms
 

Players bullish on VRUS are also bullish on:

Players bearish on VRUS are also bearish on:

Ticker Tags

Drug Manufacturers - Other (105), IPO in 2007 (239), Small Cap (1922), Drug Related Products (25), Micro Cap (4824)
Suggest a tag

Pharmasset, Inc. At A Glance

Current Price: $19.66
Last Trade Time: 7/18/2008 4:00 PM
Open: $20.08
Previous Close: $19.98
Daily Range: $19.57 - $20.48
52-Week Range: $9.00 - $36.44
Volume: 105,685
Market Cap: $463.58M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

VRUS VS S&P 500 (SPY)

VRUS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for VRUS

More Headlines...

Top Bull Pitch

Recs

1

Pharmasset, Inc. (VRUS)

Avatar TMFBreakerBrian (99.60) Submitted: 3/31/08 1:37 PM

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV drug.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

4

Pharmasset, Inc. (VRUS)

Avatar majakblue (79.94) Submitted: 1/19/08 12:48 AM

Ridiculous run-up. Typical pharma wannabe IPO. It probably will outperform initially as investors raise the price artificially high, and then tank as it becomes clear that the company will not be profitable for years to come if ever. It would be a good investment if you want to time the market. Ge...More

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Recs

0

 (VRUS)

Avatar cashsage (< 20) Submitted: 7/03/08 1:50 PM : Underperform Start Price: $18.69 VRUS Score: -5.80

VRUS is one of the companies with a too high valuation compared to its sales potential.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRUS)

Avatar ScreenerStizBear (< 20) Submitted: 6/26/08 2:26 PM : Underperform Start Price: $19.04 VRUS Score: -5.56

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRUS)

Avatar Rep07 (97.22) Submitted: 6/17/08 11:44 AM : Underperform Start Price: $20.10 VRUS Score: -5.17

Show me why this is worth so much. We're into a bear market so it better be good. Meanwhile ima short this sucka

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (VRUS)

Avatar zzlangerhans (89.62) Submitted: 6/17/08 10:28 AM : Underperform Start Price: $20.14 VRUS Score: -5.14

No change in fundamentals. It just seems like we've drifted a little high and we're due for a correction. It's going to be a while before any significant positive catalysts.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (VRUS)

Avatar TMFBreakerBrian (99.60) Submitted: 3/31/08 1:37 PM : Outperform Start Price: $18.01 VRUS Score: 14.07

Top HCV polymerase inhibitor on the block right now. Look for combo treatments with the protease inhibitors. Roche is the ideal partner for any anti-HCV drugmaker... Plus a little bit of extra pipeline to boot although not as exciting as its anti-HCV drug.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackPacificGrow 85.90 05/21/08 Outperform NS $17.74+10.82%-9.75%+20.57
TrackUBS 96.19 04/02/08 Outperform NS $20.00-1.70%-8.17%+6.47
TrackMerrimanCo < 20 03/11/08 Outperform NS $15.60+26.03%-3.57%+29.60
TrackSusquehanna < 20 12/07/07 Outperform NS $14.15+38.94%-16.75%+55.69
TrackJMP < 20 06/07/07 Outperform NS $8.90+120.90%-16.83%+137.73
TrackBofASec 96.91 06/06/07 Outperform NS $9.00+118.44%-17.57%+136.01

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners